PATENT CLAIM ANALYSIS

Application Number: 16035896
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "171000"]

Abstract:
This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

Claim (Index 1):
A method for treating Cushing's syndrome in a patient characterized by hypercortisolism, comprising:\n selecting a patient in need of treatment for Cushing's syndrome characterized by hypercortisolism; administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising: at least one glucocorticoid receptor (GCR) antagonist selected from the group consisting of ORG 34517, 11-(substituted phenyl)-estra-4, 9-diene derivatives, and 11-(substituted phenyl)-estra-4, 9-diene derivatives of formula 1 wherein A is a residue of a 5- or 6-membered ring containing 2 heteroatoms which are not connected to each other and independently selected from O and S, the ring being optionally substituted with one or more halogen atoms, or A is a residue of a 5- or 6-membered ring wherein no double C\u2014C bonds are present, containing 1 heteroatom selected from O and S, which the heteroatom is connected to the phenyl group at the position indicated with an asterisk, the ring being optionally substituted with one or more halogen atoms; R 1  is H or 1-oxo(1-4C)alkyl; R2 is H, (1-8C)alkyl, halogen or CF3; Xis selected from (H 2 OH), O, and NOH; and the interrupted line represents an optional bond; and\n at least one pharmaceutically acceptable excipient, \n thereby treating Cushing's syndrome characterized by hypercortisolism in the patient.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 95.0
- Lexical Diversity: 1.53846
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15095248', '14100714', '13364651', '14801939', '14982139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7997506677820393
- 35 USC 102 Novelty (BERT): 0.563364050532964
- Combined Prediction Score: 0.7761120060571318
- Mean Citation Score: 416.731476
- Max Citation Score: 450.52133
- Similarity Product: 385.5051210435944

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test